We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+58.72%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.79B
AUM Growth
+$202M
Cap. Flow
-$337M
Cap. Flow %
-18.85%
Top 10 Hldgs %
65.26%
Holding
83
New
17
Increased
15
Reduced
17
Closed
21

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$37.7M
2
CBAY
Cymabay Therapeutics
CBAY
+$25.1M
3
INCY icon
Incyte
INCY
+$16.8M
4
SYK icon
Stryker
SYK
+$16.7M
5
KURA icon
Kura Oncology
KURA
+$16.4M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$77.4M
2
DXCM icon
DexCom
DXCM
+$54.2M
3
IDXX icon
Idexx Laboratories
IDXX
+$34.1M
4
AZN icon
AstraZeneca
AZN
+$33.3M
5
ELAN icon
Elanco Animal Health
ELAN
+$27.4M

Sector Composition

Rank Sector Weight
1 Healthcare 97.24%
2 Consumer Staples 1.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$437M 24.45%
1,381,149
– –
RYZB
2
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$150M 8.41%
2,419,528
– –
NTRA icon
3
Natera
NTRA
$37.5B
$97.1M 5.43%
1,550,280
-1,550,280
-50% -$77.4M
ASND icon
4
Ascendis Pharma A/S
ASND
$16.7B
$95M 5.31%
754,032
– –
MRK icon
5
Merck
MRK
$324B
$93.5M 5.23%
857,971
+129,567
+18% +$13.4M
JBIO
6
Jade Biosciences
JBIO
$1.22B
$85.1M 4.76%
107,391
– –
AZN icon
7
AstraZeneca
AZN
$263B
$57.3M 3.2%
425,289
-256,129
-38% -$33.3M
VERA icon
8
Vera Therapeutics
VERA
$2.54B
$53.3M 2.98%
3,467,156
– –
IDYA icon
9
IDEAYA Biosciences
IDYA
$3.41B
$51.9M 2.9%
1,458,881
+421,694
+41% +$12.6M
IMGN
10
DELISTED
Immunogen Inc
IMGN
$45.9M 2.57%
1,546,902
-498,300
-24% -$9.92M
ISRG icon
11
Intuitive Surgical
ISRG
$121B
$42.8M 2.4%
126,959
-46,318
-27% -$13.8M
LLY icon
12
Eli Lilly
LLY
$1.07T
$37.6M 2.1%
+64,525
New +$37.7M
CYTK icon
13
Cytokinetics
CYTK
$11B
$34.6M 1.93%
414,207
-645,957
-61% -$23.4M
CLDX icon
14
Celldex Therapeutics
CLDX
$2.77B
$33.5M 1.87%
844,008
+419,749
+99% +$12.3M
CBAY
15
DELISTED
Cymabay Therapeutics
CBAY
$33.3M 1.87%
+1,411,769
New +$25.1M
IMTX icon
16
Immatics
IMTX
$1.24B
$31.3M 1.75%
2,969,039
-282,470
-9% -$2.6M
SNY icon
17
Sanofi
SNY
$104B
$29.8M 1.67%
598,978
-96,397
-14% -$4.71M
INBX
18
DELISTED
Inhibrx, Inc. Common Stock
INBX
$29.4M 1.64%
772,957
+29,663
+4% +$636K
KVUE icon
19
Kenvue
KVUE
$37B
$26M 1.45%
1,206,939
-595,145
-33% -$11.9M
KURA icon
20
Kura Oncology
KURA
$922M
$24M 1.34%
+1,667,321
New +$16.4M
SNDX icon
21
Syndax Pharmaceuticals
SNDX
$1.84B
$23.2M 1.3%
1,075,786
+133,969
+14% +$2.06M
MRNS
22
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$19.3M 1.08%
1,772,699
+787,093
+80% +$5.9M
SYK icon
23
Stryker
SYK
$127B
$18.8M 1.05%
62,788
+59,509
+1,815% +$16.7M
INCY icon
24
Incyte
INCY
$23.5B
$18.6M 1.04%
+296,569
New +$16.8M
GERN icon
25
Geron
GERN
$911M
$18.6M 1.04%
8,814,497
+5,111,951
+138% +$9.94M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2023 Portfolio in Review

As of Q4 2023, Sofinnova Investments held 83 positions worth $1.79B, up 13% from $1.59B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Sofinnova Investments withdrew a net $337M in Q4 2023, closing 21 positions and reducing 17 holdings. Its most notable exit was Idexx Laboratories, an estimated $34.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 86% a quarter earlier, followed by Consumer Staples.

Against the trend, Sofinnova Investments opened a new position in Eli Lilly worth $37.6M.

  • Sofinnova Investments's largest Q4 2023 buy was Eli Lilly: 64,525 shares worth $37.6M.
  • Sofinnova Investments added most to Stryker in Q4 2023, an estimated $16.7M increase.
  • Sofinnova Investments's biggest Q4 2023 reduction was Natera, cutting an estimated $77.4M.
  • Sofinnova Investments fully exited Idexx Laboratories in Q4 2023, selling an estimated $34.1M.
  • Sofinnova Investments's ten largest holdings make up 65% of its $1.79B portfolio in Q4 2023.
  • Sofinnova Investments opened 17 new positions and closed 21 in Q4 2023.
  • Sofinnova Investments's portfolio value rose 13% quarter-over-quarter to $1.79B.

Based on Sofinnova Investments's 13F filing for Q4 2023, filed 13 Feb 2024.